The National Institutes of Health’s Post

Scientists at the National Institutes of Health (NIH) have achieved a critical milestone in understanding the mechanisms behind the accumulation of “bad” cholesterol, or low-density lipoprotein cholesterol (LDL-C), in the body. For the first time, researchers have demonstrated how the primary structural protein in LDL interacts with its receptor, initiating the process of LDL clearance from the bloodstream. They also identified the consequences of disruptions in this process. Published in Nature, the findings enhance our knowledge of how LDL contributes to heart disease—the leading cause of death worldwide—and may pave the way for more tailored LDL-lowering therapies, such as personalized statin treatments, to improve their effectiveness. 11 December 2024, Nature. DOI: 10.1038/s41586-024-08223-0 https://lnkd.in/e5pcipnx

Elevated IGF2BP1 expression was associated with poor prognosis in HCC patients. IGF2BP1 is an oncogenic factor that accelerates HCC aerobic glycolysis and oxaliplatin resistance. IGF2BP1 could be a potential therapeutic target in HCC, aiming to disrupt the interplay between aberrant metabolism and immune escape. https://lnkd.in/dzAyWkd9

Biomarkers for type 2 diabetes identified in the gut microbiota 🎯 New insights on the microbiome’s impact on diabetes pathogenesis create future pathways for diagnosis. https://lnkd.in/gj4pnacr #generalpractice #primarycare #familymedicine #diabetes

A potential candidate to improve healthspan and lifespan in aging field. Caloric restriction has profound impact on lifespan of several organisms, and this beneficial correlation is associated with the reduction of tissue senescent cells. Inhibition of sodium glucose co-transporter 2 (SGLT2) promotes the drainage of calories through urinary excretion of glucose. The study indeed established the fact that SGLT2 inhibitor, a drug routinely prescribed to treat diabetes and cardiovascular disease, attenuates pathological aging phenotypes and prevents the accumulation of senescent cells.

📚💡A tau dephosphorylation-targeting chimeraselectively recruits protein phosphatase-1 to ameliorate Alzheimer’s disease and tauopathies

Researchers identify protein IL-35 as potential diabetes treatment - https://bit.ly/4fBM3T3 | #diabetestreatment #InstituteofAdvancedStudyinScienceandTechnologyIASST #proteinIL35 #Researchers #Type1Diabetes

🌟 New Insights on Non-Alcoholic Fatty Liver Disease (NAFLD)! 🌟 We're excited to highlight recent research exploring GW9662, a selective PPARγ antagonist, and its potential in combating NAFLD—a growing global health concern driven by insulin resistance. 👏 A recent study published in Metabolism demonstrated that GW9662 significantly attenuates the progression of NAFLD in a mouse model. Mice fed a high-fat, high-fructose, and high-cholesterol diet showed remarkable improvements when treated with GW9662, despite similar caloric intake. 🎈 Key findings include: ✅ Reduced levels of bacterial endotoxin in portal plasma. ✅ Lower expression of inflammatory markers like TLR4 and IL-1β in the liver. ✅ Decreased nitrite concentration, indicating reduced nitric oxide production. These results suggest that GW9662 effectively mitigates inflammatory responses associated with NAFLD, offering a promising avenue for treatment. 👉 For further reading, check out the full article here: https://lnkd.in/geZMQsKB Let’s continue to advance our understanding of liver diseases and explore innovative therapeutic strategies! #NAFLD #GW9662 #PPARγ #LiverHealth #Inflammation #ResearchInnovation #Metabolism

Glad to share my #publication on diagnostic utility of serum ferritin in identifying liver fibrosis in patients with non-alcoholic fatty liver disease (NAFLD) Highlights of this paper: * Serum ferritin levels were significantly higher in participants with NAFLD. * Serum ferritin levels were significantly higher in NAFLD participants with significant fibrosis, compared to those with simple steatosis. * Serum iron and ferritin had a significant positive association with NAFLD * Serum ferritin had a significant positive association with median liver stiffness parameter (LSM), which is the index of liver fibrosis in participants with NAFLD. #NAFLD #Ferritin #Fibrosis #Iron #Metabolicsyndrome https://lnkd.in/gWC7WCpw

igh-density lipoprotein cholesterol (HDL-C), the "good cholesterol," transports cholesterol from the arteries to the liver for elimination. Previous studies have demonstrated an association between higher HDL-C and lower cardiovascular (CV) risk. Epidemiologic studies reported CV disease (CVD) reductions of around 2%-3% for every unit rise in HDL-C level. However, a recently published prospective, multicenter, cohort study found that very high levels of HDL-C (> 80 mg/dL [> 2.069 mmol/L]) were associated with adverse outcomes in patients with coronary heart disease (CHD), suggesting that hyperalphalipoproteinemia (HALP) can negatively affect CV mortality.

The promising results from the trials of muvalaplin and zerlasiran signify a critical advancement in addressing elevated lipoprotein(a), especially considering the long-standing gap in treatment options for this risk factor. The impressive reductions in Lp(a) levels highlight the potential impact these therapies could have on global cardiovascular health, particularly for populations at higher genetic risk. As discussions progress towards late-stage trials, the focus will likely shift to verifying the long-term efficacy and safety of these treatments, which could fundamentally change the landscape of cardiovascular disease management. The excitement surrounding these innovations not only reflects advancements in pharmacotherapy but also underscores the importance of increasing awareness about Lp(a) among healthcare providers and patients alike. #CardiovascularHealth #CholesterolTreatment #InnovativeTherapies #HeartHealth #LipidsResearch